Ovid Therapeutics Inc.
OVID Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.16
KIRA · Stoqly’s AI analyst, in plain words
- Ovid Therapeutics Inc. had $7.3M of revenue in fiscal 2025, up 1,181.3% on the year before. Over five years, revenue changed −10.5% a year on average.
- Its operating margin was −585.2%, up 10,348.5 pts: of every 100 in sales, about −585 is left after running the business.
- Ovid Therapeutics Inc. lost $17.4M in fiscal 2025.
- Free cash flow was −$38.3M in fiscal 2025, −528.6% of revenue.
Market cap
—
P/E
—
Revenue
$7.3M
Net income
−$17.4M
Free cash flow
−$38.3M
Operating margin
−585.2%
Ovid Therapeutics Inc. in 30 seconds · fiscal 2025
Are sales growing?
+1,181.3%
Yes. Sales grew 1,181.3% last year.
Does it make a profit?
−240.1%
No. It lost money last year.
Does profit turn into cash?
−528.6%
No. It spent more cash than it brought in.
What Ovid Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- Ovid Therapeutics Inc.
- CIK
- 0001636651
Ovid Therapeutics Inc. · OVID
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $208M | $1.5M | $0.4M | $0.6M | $7.3M |
| Revenue growth | 1,551.6% | −99.3% | −73.9% | 44.4% | 1,181.3% |
| Operating margin | 59.6% | −3,696.6% | −15,122.7% | −10,933.7% | −585.2% |
| Net income | $123M | −$54.2M | −$52.3M | −$26.4M | −$17.4M |
| Net margin | 58.9% | −3,604.8% | −13,351.8% | −4,670.1% | −240.1% |
| Diluted EPS | $1.76 | −$0.77 | −$0.74 | — | — |
| Cash | |||||
| Cash from operations | $119M | −$55.2M | −$45.8M | −$56.0M | −$38.3M |
| Capital expenditure | $0.2M | $1.2M | $0.0M | $0.1M | $0.0M |
| Free cash flow | $118M | −$56.5M | −$45.8M | −$56.0M | −$38.3M |
| FCF margin | 56.8% | −3,756.7% | −11,689.0% | −9,898.8% | −528.6% |
| Share count change | 16.5% | 3.5% | 0.2% | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $188M | $129M | $106M | $53.1M | $69.6M |
| Shareholders' equity | $180M | $132M | $87.8M | $68.2M | $131M |
| Current ratio | 12.9x | 18.8x | 9.6x | 5.3x | 9.0x |
| Returns and quality | |||||
| Return on equity | 110.0% | −34.7% | −47.6% | −33.9% | −17.5% |
| Return on tangible equity | 66.7% | −41.0% | −59.7% | −38.8% | −13.3% |
| Piotroski F-score | 5 | 1 | 1 | — | — |
| Altman Z'' | 20.1 | 4.2 | −2.9 | −9.1 | 0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ovid Therapeutics Inc. · OVID
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.16 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001636651). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.